Cargando…

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

BACKGROUND: Doxorubicin and cyclophosphamide (AC) therapy is an effective treatment for early-stage breast cancer. Doxorubicin is a substrate for ABCB1 and SLC22A16 transporters. Cyclophosphamide is a prodrug that requires oxidation to 4-hydroxycyclophosphamide, which yields a cytotoxic alkylating a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bray, J, Sludden, J, Griffin, M J, Cole, M, Verrill, M, Jamieson, D, Boddy, A V
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844036/ https://www.ncbi.nlm.nih.gov/pubmed/20179710 http://dx.doi.org/10.1038/sj.bjc.6605587

Ejemplares similares

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma
por: Veal, Gareth J., et al.
Publicado: (2016)

Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells
por: Bruynzeel, A M E, et al.
Publicado: (2007)

The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study
por: Bruynzeel, A M E, et al.
Publicado: (2007)

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
por: Pichot, C S, et al.
Publicado: (2009)

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
por: Helsby, N A, et al.
Publicado: (2008)

Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor
por: Jamieson, D, et al.
Publicado: (2006)

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population
por: Barnett, Shelby, et al.
Publicado: (2021)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
por: Orlandi, P, et al.
Publicado: (2013)

Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells
por: Pero, S C, et al.
Publicado: (2007)

Phellinus linteus sensitises apoptosis induced by doxorubicin in prostate cancer
por: Collins, L, et al.
Publicado: (2006)

Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
por: Graat, H C A, et al.
Publicado: (2006)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile
por: Giovannetti, E, et al.
Publicado: (2005)

Phenformin as prophylaxis and therapy in breast cancer xenografts
por: Appleyard, M V C L, et al.
Publicado: (2012)

Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes
por: Calcagno, A M, et al.
Publicado: (2008)

The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines
por: Kostrzewa-Nowak, D, et al.
Publicado: (2005)

Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model
por: Chiu, B, et al.
Publicado: (2014)

Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity
por: Rephaeli, A, et al.
Publicado: (2007)

The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-κB
por: Jacobs, H, et al.
Publicado: (2011)

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
por: Lorusso, D, et al.
Publicado: (2012)

The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity
por: Hemmerle, T, et al.
Publicado: (2013)

Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells
por: de Groot, D J A, et al.
Publicado: (2005)

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
por: Cheriyath, V, et al.
Publicado: (2011)

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)
por: Lévi, Francis, et al.
Publicado: (2017)

Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1
por: de Groot, D J A, et al.
Publicado: (2007)

Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human osteosarcoma xenografts
por: Eikenes, L, et al.
Publicado: (2005)

TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy
por: Pirovano, Giacomo, et al.
Publicado: (2017)

Attenuated reovirus displays oncolysis with reduced host toxicity
por: Kim, M, et al.
Publicado: (2011)

Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells
por: Armstrong, J L, et al.
Publicado: (2005)

Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut
por: Bach, S P, et al.
Publicado: (2006)

Epstein–Barr virus renders the infected natural killer cell line, NKL resistant to doxorubicin-induced apoptosis
por: Isobe, Y, et al.
Publicado: (2008)

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
por: Meulendijks, Didier, et al.
Publicado: (2017)

Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
por: Vinjamuri, S, et al.
Publicado: (2013)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome
por: Ryan, J, et al.
Publicado: (2012)

γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate
por: Kim, S-E, et al.
Publicado: (2013)

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
por: Murray, J, et al.
Publicado: (2014)

Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead
por: Mangoni, M, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7f8s1mqais6rlc0cqct1l8hh9k